摘要
目的探究代偿期乙型肝炎肝硬化患者在治疗过程中应用恩替卡韦对其血清甲状腺激素水平的影响。方法于2017年5月至2019年5月随机选取本院收治的代偿期乙型肝炎肝硬化患者90例,全部患者在常规治疗基础上加用恩替卡韦治疗,每次选择0.5 mg,每日1次,持续治疗6个月。利用化学免疫发光法对患者治疗前与治疗后6个月时的总三碘甲状腺原氨酸、促甲状腺激素、甲状腺素、游离总甲状腺素以及游离三碘甲状腺原氨酸等甲状腺激素水平变化情况进行检测。结果全部患者中,HBV-DNA转阴患者与未转阴患者甲状腺激素水平相比于治疗前有显著的变化,差异有统计学意义(P<0.05);HBV-DNA转阴患者治疗后甲状腺激素水平明显高于未转阴患者,差异有统计学意义(P<0.05)。结论代偿期乙型肝炎肝硬化患者在治疗过程中应用恩替卡韦,在HBV-DNA转阴的同时,还可以有效调节血清甲状腺激素水平,应用价值显著。
Objective To investigate the effect of entecavir on the serum thyroid hormone level in patients with hepatitis B cirrhosis during the compensatory period.Methods During the period from May 2017 to May 2019,90 patients with hepatitis B cirrhosis were randomly selected for treatment in this hospital.All patients were treated with entecavir on the basis of routine treatment,and 0.5 mg was selected each time,once a day,continuous treatment for half a year.The changes in thyroid hormone levels such as total triiodothymidine,thyroxine,free total thyroxine,and free triiodothymidine were detected before and after the treatment of the patient.Results In all patients,the thyroid hormone level of HBV-DNA was significantly different from that before the treatment,and the difference was statistically significant(P<0.05).The thyroid hormone level of HBV-DNA was significantly higher than that of non-perverted patients after treatment,and the difference was statistically significant(P<0.05).Conclusion Enticavir can be used in the treatment of hepatitis B cirrhosis during the reimbursement period.While HBV-DNA is yin in most patients,it can also effectively regulate serum thyroid hormone levels,and its application value in hepatitis B cirrhosis patients is significant.
作者
王莹
WANG Ying(Fuxin Infectious Diseases Hospital Digestive Hepatology Division,Fuxin 123000,China)
出处
《中国医药指南》
2021年第26期126-127,共2页
Guide of China Medicine
关键词
代偿期乙型肝炎肝硬化
血清甲状腺激素
恩替卡韦
Hepatitis B cirrhosis during the compensation period
Serum thyroid hormone
Entecavir
